The Association between PON1 (Q192R and L55M) Gene Polymorphisms and Risk of Cancer: A Meta-Analysis Based on 43 Studies

Table 2

Characteristics of qualified case-control studies included in the meta-analysis of PON1- L55M.

Author	Year	Ethnicity	Genotyping Method	Control of source	Cancer Type	Case			Control			HWE
						LL	LM	MM	LL	LM	MM		p	p(HWE)
Stevens et al.	2006	Caucasian	PCR-RFLP	P-B	Breast Cancer	176	230	77	202	233	58	0.88	0.77	Y
Antognelli et al.	2009	Caucasian	PCR-RFLP	P-B	Breast Cancer	107	115	325	188	125	231	157.2	0.0001	N
Hussein et al.	2011	Caucasian	PCR-RFLP	P-B	Breast Cancer	19	21	60	35	23	6	0.58	0.44	Y
Naidu et al.	2010	Asian	PCR-RFLP	P-B	Breast Cancer	159	178	50	126	109	17	1.04	0.308	Y
Tang et al.	2017	Asian	TaqMan	P-B	Esophagogastric Cancer	971	69	1	1573	99	2	0.12	0.73	Y
Uluocak et al.	2017	Caucasian	PCR-RFLP	H-B	Prostate Cancer	19	24	6	43	45	10	0.13	0.72	Y
Wu et al.	2017	Asian	TaqMan	H-B	Breast Cancer	284	72	9	346	30	2	3.24	0.064	Y
Akkız et al.	2013	Caucasian	PCR-RFLP	P-B	Hepatocellular Carcinoma	105	81	31	101	89	27	1.12	0.29	Y
Geng R et al.	2014	Asian	TaqMan	H-B	Metastatic Gastric Cancer	11	7	0	82	7	0	0.15	0.7	Y
Vasconcelos et al.	2014	Mixed	TaqMan	H-B	Embryonal Tumors	85	56	15	177	134	25	0.023	0.95	Y
Metin et al.	2013	Caucasian	PCR-RFLP	H-B	Ovarian Cancer	33	22	0	33	19	2	0.13	0.72	Y
Vecka et al.	2012	Caucasian	PCR-RFLP	H-B	Pancreatic Cancer	24	39	10	28	37	8	0.67	0.41	Y
De Aguiar Goncalves et al.	2012	Mixed	TaqMan	H-B	Acute Leukemia	104	99	34	131	75	19	2.91	0.09	Y
Kokouva et al.	2012	Caucasian	PCR-RFLP	H-B	Hematologic Cancer	117	139	60	142	159	50	0.26	0.61	Y
Aksoy-Sagirli et al.	2011	Caucasian	PCR-RFLP	H-B	Lung Cancer	119	94	10	118	102	14	1.75	0.19	Y
Uyar et al.	2011	Caucasian	PCR-RFLP	P-B	Renal Cell Cancer	29	25	6	21	29	10	4.96	0.998	Y
Lurie et al.	2008	Mixed	TaqMan	P-B	Ovarian Cancer	14	65	192	24	145	276	0.74	0.39	Y
Ergen et al.	2010	Caucasian	PCR-RFLP	H-B	Osteosarcoma	24	23	3	21	20	9	1.14	0.29	Y
Martínez et al.	2010	Caucasian	TaqMan	H-B	Brain Tumor	11	32	30	38	94	88	2.15	0.14	Y
Arpaci et al.	2009	Caucasian	PCR-RFLP	H-B	Ovarian Cancer	27	19	5	25	27	2	2.65	0.103	Y
Van der Logt et al.	2005	Caucasian	PCR-RFLP	P-B	Colorectal Cancer	139	166	59	140	162	50	0.08	0.78	Y
Antognelli et al.	2005	Caucasian	PCR-RFLP	H-B	Prostate Cancer	120	197	67	148	169	43	0.65	0.35	Y
Herrera et al.	2015	Mixed	TaqMan	H-B	Brain Tumor	46	17	4	42	14	2	0.37	0.56	Y
J. De Roos et al.	2006	Mixed	TaqMan	P-B	Hematologic Cancer	299	307	100	282	260	69	0.59	0.44	Y
Stevens et al.	2008	Mixed	TaqMan	P-B	Prostate Cancer	481	609	165	498	575	189	1.18	0.28	Y
Wang et al.	2012	Asian	PCR-RFLP	P-B	Lung Cancer	307	47	2	166	18	0	0.49	0.49	Y
Antognelli et al.	2013	Caucasian	PCR-RFLP	H-B	Prostate Cancer	180	291	100	497	540	131	0.75	0.39	Y
Hemati et al.	2019	Asian	PCR-RFLP	H-B	Gastric Cancer	41	40	9	34	49	7	0.027	0.87	Y

Abbreviations: PCR-RFlP, polymerase chain reaction-restriction fragment length polymorphism; HWE, Hardy–Weinberg equilibrium; Y, polymorphisms conforming to HWE in the control group; N, polymorphisms not conforming to HWE in the control group; H-B, hospital based; P-B, population based.